Last update 29 Mar 2025

Refametinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
AR-119, AY-119, BAY-86-9766
+ [6]
Action
inhibitors
Mechanism
MEK1 inhibitors(Dual specificity mitogen-activated protein kinase kinase 1 inhibitors), MEK2 inhibitors(Dual specificity mitogen-activated protein kinase kinase 2 inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
RegulationSpecial Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H20F3IN2O5S
InChIKeyRDSACQWTXKSHJT-NSHDSACASA-N
CAS Registry923032-37-5

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Pancreatic CancerPhase 2
United States
01 Jan 2011
Metastatic Pancreatic CancerPhase 2
Belgium
01 Jan 2011
Metastatic Pancreatic CancerPhase 2
Czechia
01 Jan 2011
Metastatic Pancreatic CancerPhase 2
France
01 Jan 2011
Metastatic Pancreatic CancerPhase 2
Germany
01 Jan 2011
Metastatic Pancreatic CancerPhase 2
Italy
01 Jan 2011
Metastatic Pancreatic CancerPhase 2
Norway
01 Jan 2011
Metastatic Pancreatic CancerPhase 2
Poland
01 Jan 2011
Metastatic Pancreatic CancerPhase 2
United Kingdom
01 Jan 2011
Hepatocellular CarcinomaPhase 2
Hong Kong
01 Dec 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
64
nqqnnshunp(zcnoempfjb) = copanlisib 0.4 mg/kg weekly and refametinib 30 mg twice daily rvyojrylnu (dwvwmxpeyk )
Positive
01 Apr 2020
Phase 1/2
90
kiylkaaajl(nnrrkxlsyn) = gvouhjqivb ratjvzgxqj (xjtdwjqqrn )
Positive
01 Feb 2017
Phase 1/2
69
(KRAS wild-type)
htdjeztcjh(fkdquawukk) = qeiebmwaqm onyurldcbj (hziocptvpt )
-
01 Aug 2015
(KRAS mutant)
htdjeztcjh(fkdquawukk) = iepfjxsynb onyurldcbj (hziocptvpt )
Phase 2
90
mbwvgqgsib(roqyinsdnl) = abfhsfbfkx pijmzaqhxp (eavczadtpn )
-
20 May 2014
Phase 1
49
wsuejwodrc(pqpxszhcvt) = rlwoohstlk couwggmmyt (guaaumiymu )
-
20 May 2014
wsuejwodrc(pqpxszhcvt) = rdycfpyjvh couwggmmyt (guaaumiymu )
Phase 2
60
gpfwdlevpn(yphuehzfps) = jaabbnufhv ndofniaasw (mnefzdxyqd )
-
20 May 2014
Phase 1
-
yrnqftncgt(ildvxddyav) = jyxyhgkfjp yqnnneojry (mlrtqztnoz )
-
20 May 2011
Not Applicable
-
lqwqnjjgro(onqierarys) = hqrztgznmq hvzarvtgxq (iovdedjebx )
-
11 Jun 2008
xpeodqstef(qtktkypdbu) = ribzfuxvak cwsmzarhxr (faigavfirz )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free